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Abstract: Background: Unsaturated C18 fatty acids, such as oleic acid (L1), linoleic acid 
(L2), and linolenic acid (L3), are a good choice of lipids to prepare liposomes. They are 
inexpensive, biocompatible, nontoxic, and readily available compared with phospholipids. 
Moreover, cis-double bonds of unsaturated fatty acids prevent the packing of molecules 
which increases membrane fluidity in liposomes making them a good choice of starting 
materials to prepare liposomes.  
Objective: Unsaturated C18 fatty acid liposomes, as well as their PEGylated and non-
PEGylated antibody-targeted liposomes, were prepared and characterized. 
Method: The particle size and zeta potential of the prepared liposomes (1 mM, pH = 7.4) for 
28 and 14 days, respectively, were monitored and characterized. Membrane-bound 
antibodies Anti-SNAP25 (AS25) and DOPE PEG2000 (DP) were conjugated to pure C18 
fatty acid liposomes to achieve stable fatty acid formulations.  
Results: The mean particle sizes of pure L1, L2, and L3 liposome solutions were 125, 129, 
and 122 nm respectively, while their polydispersity index values were 0.28, 0.21, and 0.40 
respectively. A large negative zeta potential value of 45 mV was observed due to anionic 
carboxylate head-group of pure liposomes. The incorporation of AS25 into L1/DP, L2/DP, 
and L3/DP liposome solutions stabilized their mean particle size and zeta potential 
measurements over 28 and 14 days, respectively. 
Conclusion: L1/DP/AS25 was found to be the most stable PEGylated antibody-targeted 
liposome system because its particle size remained between 90 and 125 nm in 28 days. 
Transmission electron microscopy observations also supported the incorporation of AS25 
and DP on the membrane surface as predicted. 
Keywords: Stealth liposomes, drug delivery systems, therapeutic proteins, biotechnology, nanotechnol-
ogy, Liposomes. 
1. INTRODUCTION 
Proteins and peptides are important bioactive 
macromolecules that offer numerous advantages  
of highly specific and effective therapeutic  
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mechanisms of actions. Peptides that are highly 
specific small biomolecules act as substrates, in-
hibitors, or regulators and play important roles in 
monitoring biological functions [1]. For example, 
insulin as a peptide hormone is one of the most 
widely used drugs for diabetes. Due to their 
physiochemical properties, peptides have limited 
ability to cross cell membranes to reach intracellu-
lar target sites. Most peptides, thus, need to be en-
trapped into nanoscale delivery systems to effi-
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ciently facilitate their intracellular delivery. Pro-
tein therapeutics are also limited by several phar-
maceutical issues, such as high molecular weight, 
and in vitro and in vivo short half-lives. These is-
sues cause side effects, such as immunogenicity, 
resulting from repeatable injections of rapidly de-
gradable protein drugs over a long diagnostic pe-
riod. In addition, there is a lack of an effective way 
to deliver functional proteins across plasma mem-
branes due to their large molecular size and bio-
chemical properties [2-4]. Therapeutic proteins, 
such as antibodies, can be conjugated onto the sur-
face of liposomes. Besides, nucleic acids 
(DNA/RNA), virus antigens, and therapeutic en-
zymes can be encapsulated into liposomes. 
Antibody-targeted liposomes are made of con-
jugating antibodies to the lipid bilayer of a 
liposome surface, which promotes a specific inter-
action with cancer cells [5-8]. Pharmacokinetic 
analysis and therapeutic studies reveal that anti-
body-targeted liposomes have considerable poten-
tial to be used as a drug delivery system for cancer 
therapy. Such a system optimizes the drug delivery 
to tumor cells, reduces the exposure of highly 
toxic anticancer drug to healthy cells, and mini-
mizes side effects [9-12].  
Unsaturated C18 fatty acids are a good choice 
of lipids to prepare liposomes [13, 14] as they are 
inexpensive, biocompatible, nontoxic, and readily 
available. Moreover, the cis-double bond(s) of un-
saturated fatty acids make them the good choice of 
starting material to prepare liposomes. The pres-
ence of a cis-double bond prevents the packing of 
molecules, which increases the membrane fluidity 
in liposomes. Membrane fluidity allows drug en-
capsulation and conjugation of the antibody. We 
have reported the preparation of stealth and non-
stealth fatty acid liposomes and their capability in 
drugs encapsulation [15-17]. The most notable 
drawback of fatty acid liposomes is their physical 
and chemical instabilities during storage. In fact, 
this is a general drawback for most of liposomal 
formulations, including some phospholipid 
liposomes. Therefore, membrane-bound antibodies 
and poly(ethylene glycol) can be conjugated to 
pure C18 fatty acid liposome solutions (as illus-
trated in Fig. 1) to stabilize fatty acid formulations, 
because lipid-protein interactions naturally occur 
in biological membranes. 
 
In the present work, we prepared liposomes of 
unsaturated C18 fatty acids with the incorporation 
of Anti-SNAP25 (AS25) and DOPE PEG2000 
(DP). The particle size and zeta potential of the 
prepared liposomes for 28 and 14 days, respec-
tively, were monitored and characterized. This re-
search serves as the outcome of our previous stud-
ies on intermolecular interactions between AS25 
(and DP) and C18 fatty acids using Langmuir 
technique [18, 19]. Briefly, AS25 is a membrane-
bound, presynaptic nerve terminal protein that 
plays an essential role in vesicle membrane fusion 
events with the plasma membrane. SNAP-25 is a 
soluble protein having a molecular weight of 25 
kDa, which contains 206 amino acids [20]. Mem-
brane fusion is a vital process in biological sys-
tems and facilitates the transport of molecules 
across a membrane. It is crucial for the entry of 
encapsulated drugs into the targeted site [21]. 
Membrane fusion during intracellular transport is 
 
Fig. (1). A schematic diagram illustrates the surface of (a) liposomes, (b) antibody-targeted liposomes, (c) stealth liposomes, 
and (d) stealth antibody-targeted liposomes. 
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thought to be mediated by a large family of pro-
teins known as soluble N-ethylmaleimide-sensitive 
factor protein receptors (SNARE) proteins.  
This study plays an important role in develop-
ing new antibody-targeted liposome formulations. 
This work serves as a useful reference to improve 
fatty acid liposome formulations that are currently 
overlooked. 
2. MATERIALS AND METHODS 
2.1 Materials 
C18 fatty acids, such as oleic acid (cis-9-
octadecenoic acid, ≥ 99%), linoleic acid (cis, cis-
9,12-octadecadienoic acid, ≥ 99 %), linolenic acid 
(cis, cis, cis-9,12,15-octadecatrienoic acid, ≥ 
99%), and AS25 (Product number S9684) were 
purchased from Sigma-Aldrich (Palo Alto, CA, 
USA). AS25 was supplied as an IgG fraction of 
antiserum (using rabbit as host species) in 0.01 M 
phosphate-buffered saline (PBS) of pH = 7.4, con-
taining 15 mM sodium azide as a preservative. The 
concentration of AS25 was 9.55 µg/µl. It was 
stored at -20°C in a freezer. 1,2-dioleoyl-sn-
glycero-3-phosphoethanolamide-N-
[methoxy(polyethyleneglycol)-2000] (ammonium 
salt), DOPE PEG2000 (DP) having molecular 
weight of 2801.47 amu, was purchased from 
Avanti Polar Lipids, USA. DP is a white powder 
that was kept at -20°C in a freezer when not in use. 
Analytical grade chloroform (CHCl3) was pur-
chased from Merck, USA and used to dissolve lip-
ids. CHCl3 was double-distilled at its boiling point 
(61.2°C) before use. PBS tablets were purchased 
from Sigma-Aldrich. One tablet of PBS that was 
completely dissolved in 200 ml of distilled water 
yielded 0.01 M PBS (pH 7.4) at 25°C. Phospho-
tungstic acid (PTA) hydrate for transmission elec-
tron microscopy (TEM) negative staining was pur-
chased from Fluka and stored in a desiccator when 
not in use. 
2.2. Preparation of Unsaturated C18 Fatty Ac-
ids/AS25, C18 Fatty Acids/DP, and C18 Fatty 
Acids/DP/AS25 Liposomes 
Oleic acid (L1) liposome solution of 1 mM was 
prepared by mixing L1 in 1 ml of 0.05 M NaOH 
aqueous solution, pH of the solution was adjusted 
to 7.4 using 0.05 M HCl. Subsequently, the solu-
tion was topped up using 0.01 M PBS solution in a 
5 ml volumetric flask. The procedures for prepar-
ing stock solutions of linoleic acid (L2) and lino-
lenic acid (L3) were the same. A desired volume 
of AS25 (10, 25, 50, 75, or 100 µl) was added into 
1 mM of L1, L2, and L3 liposome solutions [18] 
using a Hamilton microsyringe that was precise to 
0.5 µl. The mixtures were stirred overnight before 
characterizations. 
C18 fatty acids/DP liposomes were prepared by 
lipid thin-film hydration method [22, 23]. Briefly, 
various mole ratios of L1/DP, L2/DP, and L3/DP 
were mixed in CHCl3 in a round bottom flask. 
Thin films of lipids were created on the flask using 
a rotary vacuum evaporator to remove the residual 
organic solvent. The dry film was then hydrated 
using 0.01 M PBS to swell the convolute into 
liposomes. The resulting solutions were adjusted 
to pH 7.4 using 0.05 M NaOH or HCl. Subse-
quently, sonication of the solution was performed 
to break multi-lamellar films into simple sheets of 
lamellar structures that eventually formed uni-
lamellar liposomes. The suspension was then 
topped up with PBS solution. The mole ratio of 
C18 fatty acids/DP liposomes at 1 to 0.02 (or 50 to 
1) was selected by referring to their stability as-
sessment as shown in Fig. (2) and our previous LB 
findings [19]. The same volume of AS25 as above 
was added to individual vials containing 5 ml of 1 
mM C18 fatty acids/DP liposome solutions. The 
amount of AS25 that was added into C18 fatty ac-
ids and C18 fatty acids/DP liposome solutions 
were expressed in 3.6, 7.40, 16.8, and 25.2 nmole, 
as shown in Figs. (4-7). Both C18 fatty acids/DP 
liposomes and antibody-targeted C18 fatty ac-
ids/DP liposome solutions were stirred overnight 
before characterization. 
2.3. Measurement of Particle Size and Zeta Po-
tential 
Mean particle size of liposomes, zeta potential, 
and Polydispersity Index (PDI) are commonly 
monitored parameters. The mean vesicle size and 
zeta potential were measured by dynamic light 
scattering (DLS) using Malvern Nano ZS (Mal-
vern Instruments Ltd. UK). Using a disposable sy-
ringe, 1.0 ml of liposomes was carefully trans-
ferred into 1 cm path length four-sided clear fluo-
rescent quartz cuvette. The liposomes were ana-
lyzed using pre-set standard operation procedure 
for DLS to measure the average hydrodynamic 
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size of liposomes and zeta potential measurements. 
A 4 mW He-Ne laser was employed to generate 
the laser beam that was detected by the backscat-
tered detector at 173° with respect to the scattering 
transmission beam. The scattered beam passed 
through the sample and then directed to compensa-
tion optic at 17° from the scattering beam. The 
fluctuation in the frequency of the scattered beam 
was detected by the detector and its intensity was 
analyzed by the Malvern software. All measure-
ments were performed in triplicate at 25°C. 
2.4. TEM Imaging 
A drop of liposome solution was placed onto 
the high-quality formvar-coated copper grid (400 
square mesh) and allowed to stand for 3 min. The 
excess of solution was blotted with filtered paper, 
stained with 1% (w/v) PTA for 1 min, and allowed 
to air dry. The specimens were kept in a desiccator 
for 2 to 3 days and allowed to dry. Negative stain-
ing using PTA solution is an easy and widely used 
method for examining liposome structures at 
electron microscopy level. However, negative 
staining involves deposition of heavy atom stains 
(in this case, tungsten) because flattening of 
spherical or cylindrical liposome structures is 
commonly observed. PTA stained liposomes show 
bilayer moiety due to their strong affinity to PTA 
and become very electron-dense [24]. The images 
of liposomes were obtained by using Zeiss Libra® 
120 TEM operated at an accelerating voltage of 
120 kV. 
3. RESULTS AND DISCUSSION 
3.1. Particle Size and Zeta Potential Analysis of 
C18 Fatty Acids and C18 Fatty Acids/DP 
Liposomes 
The mean particle size of pure L1, L2, and L3 
liposomes solution (pH 7.4) were 125, 130, and 
120 nm respectively (Fig. 2). Their PDI values 
were 0.28, 0.21, and 0.40 respectively. Generally, 
PDI describes the uniformity degree of size distri-
bution of particles. For a monodisperse sample, its 
PDI value is considered to be less than 0.1. PDI of 
more than 0.5 suggests a broad distribution sample 
of mono-modal, reasonably narrow, and spherical 
samples. The stability assessment on pure 
liposome solutions demonstrated that the particle 
size was stable and remained less than 200 nm in 
a)     b) 
 
    c) 
 
Fig. (2). Mean particle size of C18 fatty acid/DP liposomes: (a) L1/DP, (b) L2/DP, and (c) L3/DP for 28 days at 30°C. For ■ = 
C18 fatty acids liposomes; the mole ratio of DP to C18 fatty acids: ● = 0.01, ▲ = 0.02, ▼= 0.03, ◄ = 0.04, and ► = 0.05 in-
corporated into liposomes. 
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28 days. Their zeta potential was a large negative 
value of -45 mV due to their anionic carboxylate 
head-group. Zeta potential magnitudes of L2 and 
L3 increased to -25 and -10 mN m-1 over 14 days 
of monitoring, respectively (Fig. 3). 
 
Fig. (3). Mean zeta potential of C18 fatty acid/DP liposomes, 
(a) L1/DP, (b) L2/DP, and (c) L3/DP for 14 days at 30°C. 
For ■ = C18 fatty acids liposomes; the mole ratio of DP to 
C18 fatty acids: ● = 0.01, ▲ = 0.02, ▼= 0.03, ◄ = 0.04, 
and ► = 0.05 incorporated into liposomes. 
 
The presence of PEG increases the circulation 
time up to hours or several days by reducing se-
rum-protein binding. The rate of drug release from 
nanocarrier, thus, is reduced accordingly. PEG 
also increases the vascular penetrability of 
liposomes and facilitates the accumulation of 
drug-containing liposomes in tumor/cancer tissue 
[25-29]. The results show that the incorporation of 
DP into fatty acid liposomes did not entirely im-
prove the particle size and zeta potential stability. 
The mean particle size measurement for 28 days 
shows that of L2/DP was more stable than L1/DP 
and L3/DP (Fig. 2). The mean particle size of 
L2/DP varied closely within 50 to 200 nm. In con-
trast, variations in particle size of L1/DP and 
L3/DP liposomes were observed to fluctuate be-
tween 50 and 350 nm. Evident irregularity in par-
ticle size was observed in L3/DP at the highest 
mole ratio of DP (0.05) in the investigation range. 
The highest mole of DP (in the investigation 
range) caused the instability of liposomes after 28 
days. Zeta potential increased dramatically (Fig. 3) 
by incorporating DP into pure fatty acid liposomes 
because DP is less negative-charged than fatty ac-
ids that have an overall negative charge. From zeta 
potential measurements, L1/DP was found to be 
more stable than L2/DP and L3/DP. 
PEGs having saturated lipids such as 1,2 di-
palmitoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000] (DPPE 
PEG2000) [14, 16, 17], and 1,2-distearoyl-sn-
glycero-3-phosphoethanolamine-N-
[amino(polyethylene glycol)-2000] (DSPE 
PEG2000) [30, 31] are commonly used in numer-
ous preparations of stealth liposome (or 
immunoliposome) formulations for in vivo and in 
vitro cancer therapeutic studies. PEGs having satu-
rated lipids have neglected bends or kinks in their 
saturated lipid molecular structures that promote 
molecular packing, so they are easily inserted into 
liposome membranes. Fatty acid liposomes incor-
porated with unsaturated DOPE PEG2000 are 
slightly larger than liposomes incorporated with 
saturated DPPE PEG2000 [16, 32]. Such an 
advantage can be used to encapsulate drugs having 
large molecule sizes and increase drug encapsula-
tion efficiency of nanocarriers. The unsaturated 
DOPE hydrocarbon chains of DP increase the re-
pulsion in molecular packing of liposomes due to 
the effect of cis-double bonds of DOPE, ultimately 
increasing the size of liposomes. 
3.2. Particle Size and Zeta Potential Analysis of 
C18 Fatty Acids/AS25 Liposomes 
Irregularity in particle size was found in C18 
fatty acids/AS25 liposomes (Fig. 4). The particle 
size of L1/AS25 was increased with the increasing 
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volume of incorporated AS25 (Fig. 4a). In con-
trast, L2/AS25 and L3/AS25 did not show evident 
trend by changing the amount of AS25 (Fig. 4b 
and c). The particle size of the mixture decreased 
in less than 100 nm in 14 days. Presumably, it hy-
drolyzed into salt solutions during storage. The 
carboxyl head-group of C18 fatty acids is rather 
unstable. PDI of each mixture is slightly larger 
than that of its respective pure liposome. 
 
 
Fig. (4). Mean particle size of C18 fatty acids/AS25 liposomes: (a) 
L1/AS25, (b) L2/AS25, and (c) L3/AS25 for 28 days at 30°C.  For 
■ = C18 fatty acids liposomes; the amount of AS25: ● = 3.36 
nmole, ▲ = 7.40 nmole, ▼= 16.8 nmole, ◄ = 25.2 nmole incorpo-
rated into liposomes. 
Charged amino acids present on protein surface 
can ionize or deionize, depending on the pH, and 
can make protein a charged particle in aqueous 
solution. The surface charge of the protein is not 
static, because the charged groups are acids and 
bases that constantly exchange protons with water. 
Therefore, the surface charge of protein is in a dy-
namic equilibrium with its uncharged state. Be-
cause right surface charge on the protein’s active 
site can greatly influence the specific substrate 
binding, the surface charge of protein is important. 
Here, zeta potential measurement of AS25 in PBS 
solution (pH 7.4) was found to be -6.72 (±0.15). 
Zeta potential of C18 fatty acid/AS25 liposome 
solutions were found to be less negative than their 
highly negative pure liposome solutions. Surface 
charge of AS25 molecules is less negative than 
that of C18 fatty acid liposome solutions. There-
fore, when AS25 molecules were bounded to the 
negatively charged surface of C18 fatty acid 
liposomes, the surface charge was increased to 
make them less negative. When 3.36 nmol of 
AS25 was incorporated into L1 liposome solution, 
an increase was observed in zeta potential of 
L1/AS25 from -45 to -28 mV. By increasing the 
amount of AS25 (8.40 nmol, 16.8 nmol, and 25.2 
nmol) added into L1 liposome solution, zeta po-
tential also increased and remained between -5 and 
-10 mV (Fig. 5a). The zeta potential measured in 
14 days also remained at -5 to -10 mV. Zeta poten-
tial measurements of L3/AS25 for 14 days showed 
that the liposome solution was stable and its zeta 
potential remained between -5 and -15 mV (Fig. 
5c). However, zeta potentials of L1/AS25 and 
L3/AS25 liposome solutions were more stable 
than that of L2/AS25 for 14 days, except L2/AS25 
containing 25.2 nmol of AS25, which remained 
constant at about -5 mV for 14 days (Fig. 5b). 
3.3. Particle Size and Zeta Potential Analysis of 
C18 Fatty Acids/DP/AS25 Liposomes 
The combination of active-targeting drug deliv-
ery with PEGylation is proven to reduce the rate of 
drug clearance in blood circulation, modify drug 
distribution, or even enhance the delivery of thera-
peutic materials [33-35]. 
The incorporation of AS25 into PEGylated L1, 
L2, and L3 liposome solutions stabilized their 
mean particle size and zeta potential for 28 and 14 
days, respectively (Figs. 6 and 7). The mean parti-
cle size of L1/DP/AS25 varied from 75 to 125 nm  
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Fig. (5). Mean zeta potential of C18 fatty acids/AS25 
liposomes, (a) L1/AS25, (b) L2/AS25, and (c) L3/AS25 for 
14 days at 30°C.  For ■ = C18 fatty acids liposomes; the 
amount of AS25: ● = 3.36 nmole, ▲ = 7.40 nmole, ▼= 16.8 
nmole, ◄ = 25.2 nmole incorporated into liposomes. 
 
and remained constant for 14 days. The zeta poten-
tial of L1/DP/AS25 was less negative than that 
L1/DP having mole ratio 1 to 0.02, which varied 
from -12 to -7.5 mV. The surface charge should be 
more negative when AS25 molecules were 
bounded to L1/DP surface, because AS25 is more 
negative than DP. The irregularity of particle size 
of L2/DP/AS25 was found on day 3 of measure-
ment. The size was reduced to less than 75 nm on 
day 7 and increased again to 125 nm on day 14. 
Hydrolysis of L2/DP/AS25 may occur within 7 
days. L2/DP/AS25 might transform into oil drop-
lets on day 14. Zeta potential of L2/DP/AS25 was 
more negative than that L2/DP having mole ratio 
of 1 to 0.02. Presumably, AS25 molecules pre-
ferred to be conjugated on L2/DP liposome surface 
or to the polymer head-group of DP. Mean particle 
size of L3/DP/AS25 liposome solutions was found 
to be slightly smaller than that L3/DP having mole 
ratio of 1 to 0.02. It varied from 100 to 125 nm, 
whereas particle size of L3/DP was about 150 nm. 
In 14 days of particle size monitoring, the particle 
 
Fig. (6). Mean particle size of C18 fatty acids/DP/AS25 liposomes: 
(a) L1/DP/AS25, (b) L2/DP/AS25, and (c) L3/DP/AS25 for 28 
days at 30°C.  For ■ = C18 fatty acids/DP liposomes; the amount of 
AS25: ● = 3.36 nmole, ▲ = 7.40 nmole, ▼= 16.8 nmole, ◄ = 25.2 
nmole incorporated into liposomes. 
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size of L3/DP reduced to less than 50 nm. This 
result shows that L3/DP liposome solutions (con-
taining the most number of cis-double bonds) had 
poor stability and a short shelf life. In addition to 
the hydrolysis of carboxyl head-group of L3, the 
cis-double bonds are easily oxidized as well. Pre-
cipitations in the vials were observed for 
L2/DP/AS25 and L3/DP/AS25 liposome solutions, 
which indicate the instability in correlation to the 
increasing number of cis-double bonds in hydro-
carbon chains of C18 fatty acids. Zeta potential of 
L3/DP/AS25 was less negative than that of L3/DP, 
except the liposomes solution containing 3.36 
nmol of AS25. Zeta potential of liposomes solu-
tion containing 3.36 nmol of AS25 was found to 
be greatly less negative on the third day of moni-
toring and then remained constant between -2.5 to 
-7.5 mV till day 14 for each respective mixture. 
The PDI values of PEGylated C18 fatty ac-
ids/AS25 liposomes were found to be similar to 
those of C18 fatty acids/AS25, which varied be-
tween 0.40 to 0.55. The PDI values were larger 
than PEGylated C18 fatty acids that had a PDI 
value between 0.30 to 0.40. Aggregation would 
occur when protein molecules were present in 
liposome solutions. 
3.4. TEM Micrographs 
Figs. (8 and 9) show TEM micrographs of 1 
mM of pure L1, L2, L3, and their PEGylated 
liposomes, antibody-conjugated C18 fatty acid 
liposomes, and PEGylated antibody-conjugated 
liposomes, respectively. The particle sizes of PE-
Gylated liposomes (L1/DP, L2/DP, and L3/DP) 
were slightly larger than their pure liposomes (Fig. 
 
Fig. (7). Mean zeta potential of C18 fatty acids/DP/AS25 
liposomes, (a) L1/DP/AS25, (b) L2/DP/AS25, and (c) 
L3/DP/AS25 for 14 days at 30°C.  For ■ = C18 fatty ac-
ids/DP liposomes; the amount of AS25: ● = 3.36 nmole, ▲ 
= 7.40 nmole, ▼= 16.8 nmole, ◄ = 25.2 nmole incorporated 
into liposomes. 
 
Fig. (8). Transmission electron micrographs of: (a) 1 mM 
L1, (b) L1/DP, (c) 1 mM L2, (d) L2/DP, (e) 1 mM L3, (f) 
L3/DP liposomes at pH 7.4. 
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8). The imperfection of the outer membrane was 
observed in Fig. (9), which shows the successful 
incorporation of PEG head-group of DP and AS25 
on unsaturated C18 fatty acids liposomes. The par-
ticles sizes of liposomes containing AS25 were 
non-homogenous as shown in Fig. (9), because the 
sonication was not performed after adding mem-
brane protein AS25 during preparation. The soni-
cation of proteins may cause aggregation and cell 
lysis. 
CONCLUSION 
A rapid development of lipid-based carrier sys-
tems is important to overcome the challenges of 
therapeutic proteins delivery. Membrane-bound 
protein of AS25 has become the choice of protein 
to explore lipid-protein interactions. The incorpo-
ration of AS25 into PEGylated L1, L2, and L3 
liposome solutions stabilized their mean particle 
size and zeta potentials for 28 and 14 days respec-
tively. The mean particle size of L1/DP/AS25 var-
ied from 75 to 125 nm and remained constant for 
28 days. The zeta potential of L1/DP/AS25, which 
varied from -12 to -7.5 mV, was less negative than 
that L1/DP having the molar ratio of 1 to 0.02. 
Therefore, L1/DP/AS25 liposomal system was the 
most stable PEGylated antibody-targeted liposome 
system among the studied samples. The stability of 
C18 fatty acid liposomes was enhanced by incor-
porating proteins and PEG on the surface as pre-
dicted. However, the stability in term of shelf life 
storage of polyunsaturated fatty acid liposomal 
formulations remains a challenge. It could be in-
teresting to consider different types of polymers or 
storage temperatures to stabilize polyunsaturated 
fatty acid liposomal solutions. 
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